PMID- 35356206
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220401
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and 
      Diagnosing in High-Risk Patients.
PG  - 812832
LID - 10.3389/fonc.2022.812832 [doi]
LID - 812832
AB  - OBJECTIVE: Early detection and diagnosis of hepatocellular carcinoma (HCC) is 
      essential for prognosis; however, the imaging hallmarks for tumor detection and 
      diagnosis has remained the same for years despite the use of many new immerging 
      imaging methods. This study aimed to evaluate the detection performance of 
      hepatic nodules in high risk patients using either hepatobiliary specific 
      contrast (HBSC) agent or extracellular contrast agent (ECA), and further to 
      compare the diagnostic performances for hepatocellular carcinoma (HCC) using 
      different diagnostic criteria with the histopathological results as reference 
      standard. METHODS: This prospective study included 247 nodules in 222 patients 
      (mean age, 53.32 +/- 10.84 years; range, 22-79 years). The detection performance 
      and imaging features of each nodule were evaluated in all MR sequences by three 
      experienced abdominal radiologists. The detection performance of each nodule on 
      all MR sequences were compared and further the diagnostic performance of various 
      diagnostic criteria were evaluated. RESULTS: For those patients who underwent 
      ECA-MRI, the conventional imaging hallmark of "AP + PVP and/or DP" was 
      recommended, as 60.19% diagnostic sensitivity, 80.95% specificity and 100% lesion 
      detection rate. Additionally, for those patients who underwent HBSC-MRI, the 
      diagnostic criteria of "DWI + HBP" was recommended. This diagnostic criteria 
      demonstrated, both in all tumor size and for nodules </=2 cm, higher sensitivity 
      (93.07 and 90.16%, all p <0.05, respectively) and slightly lower specificity 
      (64.71 and 87.50%, all p >0.05, respectively) than that of the European 
      Association for the Study of the Liver (EASL) criteria. CONCLUSIONS: Different 
      abbreviated MR protocols were recommended for patients using either ECA or HBSC. 
      These provided imaging settings demonstrated high lesion detection rate and 
      diagnostic performance for HCC.
CI  - Copyright (c) 2022 Gao, Wei, Zhang, Jiang, Li, Yuan, Yao, Ye, Wan, Wei, Nie, Tang 
      and Song.
FAU - Gao, Feifei
AU  - Gao F
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wei, Yi
AU  - Wei Y
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Zhang, Tong
AU  - Zhang T
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Jiang, Hanyu
AU  - Jiang H
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Qian
AU  - Li Q
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Yao, Shan
AU  - Yao S
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Ye, Zheng
AU  - Ye Z
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wan, Shang
AU  - Wan S
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wei, Xiaocheng
AU  - Wei X
AD  - MR Research China, GE Healthcare, Beijing, China.
FAU - Nie, Lisha
AU  - Nie L
AD  - MR Research China, GE Healthcare, Beijing, China.
FAU - Tang, Hehan
AU  - Tang H
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
FAU - Song, Bin
AU  - Song B
AD  - Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
AD  - Department of Radiology, Sanya People's Hospital, Sanya, China.
LA  - eng
PT  - Journal Article
DEP - 20220309
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8959840
OTO - NOTNLM
OT  - criteria
OT  - detection
OT  - diagnosis
OT  - hepatocellular carcinoma
OT  - magnetic resonance imaging
COIS- Authors XW and LN were employed by GE Healthcare. The remaining authors declare 
      that the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2022/04/01 06:00
MHDA- 2022/04/01 06:01
PMCR- 2022/01/01
CRDT- 2022/03/31 05:28
PHST- 2021/11/10 00:00 [received]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/03/31 05:28 [entrez]
PHST- 2022/04/01 06:00 [pubmed]
PHST- 2022/04/01 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.812832 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 9;12:812832. doi: 10.3389/fonc.2022.812832. eCollection 
      2022.